摘要
目的系统评价参芪地黄汤治疗慢性肾脏病(CKD)的临床效果及安全性。方法检索知网、万方、VIP、CBM以及PubMed等数据库建库至2023年2月关于参芪地黄汤治疗CKD的随机对照试验(RCT)。用RevMan 5.4软件进行质量评价和meta分析。结果共纳入10项研究,722例患者。meta分析结果显示:试验组总有效率、内生肌酐清除率高于对照组,试验组血肌酐、血尿素氮、24 h尿蛋白定量、不良反应率均低于对照组,差异有统计学意义(P<0.05)。结论参芪地黄汤在治疗CKD方面有较好的临床效果和安全性,不局限于气阴两虚证。
Objective To systematically evaluate the clinical efficacy and safety of Shenqi Dihuang Decoction in the treatment of chronic kidney disease(CKD).Methods Randomized controlled trials(RCT)for the treatment of CKD with Shenqi Dihuang Decoction were retrieved in databases such as CNKI,Wanfang,VIP,CBM,and PubMed,with the retrieval time limit from the establishment of the database to February 2023.RevMan 5.4 software was used for quality evaluation and meta-analysis.Results A total of 10 studies were included,involving and 722 patients.The meta-analysis results showed that the total effective rate and endogenous creatinine clearance rate of the test group were higher than those of the control group,while the serum creatinine,blood urea nitrogen,24-hour urine protein quantification,and adverse reaction rate of the test group were lower than those of the control group,with differences were statistically significant(P<0.05).Conclusion Shenqi Dihuang Decoction has good clinical efficacy and safety in the treatment of CKD,not limited to deficiency of qi and yin.
作者
葛瑞
郑艳辉
GE Rui;ZHENG Yanhui(Graduate School,Nanjing University of Chinese Medicine,Jiangsu,Nanjing 210023,China;Department of Nephrology,Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine,Jiangsu,Nanjing 210001,China)
出处
《中国医药科学》
2024年第6期159-163,共5页
China Medicine And Pharmacy
基金
第四批江苏省名老中医药专家传承工作室项目:孔薇工作室(苏中医科教〔2021〕7号)
江苏省南京市科技计划项目(201803018)
南京中医药大学自然科学基金项目(XZR2021049)。
关键词
参芪地黄汤
慢性肾脏病
随机对照试验
META分析
Shenqi Dihuang Decoction
Chronic kidney disease
Randomized controlled trials
meta-analysis
